Scientific article
OA Policy
English

Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection

Published inPloS one, vol. 8, no. 2, e56991
Publication date2013
Abstract

Interferon and ribavirin therapy for chronic hepatitis C virus (HCV) infection yields sustained virological response (SVR) rates of 50-80%. Several factors such as non-1 genotype, beneficial IL28B genetic variants, low baseline IP-10, and the functionality of HCV-specific T cells predict SVR. With the pending introduction of new therapies for HCV entailing very rapid clearance of plasma HCV RNA, the importance of baseline biomarkers likely will increase in order to tailor therapy. CD26 (DPPIV) truncates the chemokine IP-10 into a shorter antagonistic form, and this truncation of IP-10 has been suggested to influence treatment outcome in patients with chronic HCV infection patients. In addition, previous reports have shown CD26 to be a co-stimulator for T cells. The aim of the present study was to assess the utility of CD26 as a biomarker for treatment outcome in chronic hepatitis C and to define its association with HCV-specific T cells.

Citation (ISO format)
SÖDERHOLM, Jonas et al. Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. In: PloS one, 2013, vol. 8, n° 2, p. e56991. doi: 10.1371/journal.pone.0056991
Main files (1)
Article (Published version)
Identifiers
Journal ISSN1932-6203
601views
205downloads

Technical informations

Creation25/03/2013 16:58:00
First validation25/03/2013 16:58:00
Update time14/03/2023 20:07:02
Status update14/03/2023 20:07:01
Last indexation30/10/2024 09:07:52
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack